fda warning about compounded semaglutide Shares Safety Data 'Adverse Events' From Weight Loss Drugs FDA warns about compounded versions

Prescription microneedle GLP-1 patches are in development but not yet FDA-approved as of mid-2026

This reduction in central fat contributes to a slimmer waistline and a lower risk of type 2 diabetes, insulin resistance, and cardiovascular disease

Before prescribing, I also make sure you have no contraindications to the particular medication prescribed, such as a history of pancreatitis, a personal or family history of a rare form of thyroid cancer called medullary thyroid cancer, or multiple endocrine neoplasia type 2

Patient stratification probably matters more than any single drug choice, because the variable results likely conceal responder subgroups

If cold intolerance is severe or accompanied by other symptoms such as fatigue, hair loss, or bradycardia, your GP should assess for these underlying conditions

This data correlated well with the free PCSK9 level which was not efficiently suppressed after day 8 (Fig